BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Maria Reig1,2,*, Alejandro Forner1,2, Jordi Rimola3, Joana Ferrer-Fàbrega4, Marta Burrel5, Ángeles García-Criado3, Robin K. Kelley6, Peter R. Galle7, Vincenzo Mazzaferrro8, Riad Salem9, Bruno Sangro2,10, Amit G. Singal11, Arndt Vogel12, Josep Fuster2,4, Carmen Ayuso10, Jordi Bruix1,2,*,†

Summary
There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer (BCLC) prognosis and treatment strategy published in 2018.1–7 Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.

© 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Introduction
There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer (BCLC) prognosis and treatment strategy published in 2018.1–7 Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Scientific evidence should be properly graded according to study design and while observational studies are informative, their limitations for robust causality inference should be acknowledged.8 While prior updates were developed solely by BCLC members, we have now included expert authors from beyond the BCLC group to integrate different expertise, insights and knowledge into this update.

Prognosis prediction and patient characterisation
While there is no controversy regarding the current stratification of patients according to tumour burden and cancer-related symptoms9,10 in prognosis prediction, the evaluation of underlying liver function, for which the Child-Pugh classification11 was already abandoned in the last BCLC version, warrants a further update. Decompensation of liver disease (jaundice, ascites, encephalopathy) reflects non-preserved liver function irrespective of the Child-Pugh or model for end-stage liver disease (MELD) score12,13 for which several improvements have been proposed,14 but compensated liver function could be stratified with additional granularity by using the albumin-bilirubin (ALBI) score,15–17 while also adding alpha-fetoprotein (AFP) concentration, irrespective of tumour burden.18,19 These parameters are now included in the 2022 BCLC model (Fig. 1), but while they may impact prognosis, they may not abolish the treatment benefit if the degree of liver dysfunction does not exceed the established selection criteria for an optimal outcome. Prior variceal bleeding also reflects more advanced liver disease with clinically significant portal hypertension (CSPH),20–22 but history thereof does not necessarily warrant its incorporation into prognosis prediction in patients with liver cancer, while it could still be an important aspect in defining treatment indication. The degree of ascites and response to therapy also impact prognosis: small radiographic ascites or fluid retention that is controlled by a low sodium diet differs from tense ascites regardless of medical treatment (diuretics and/or paracentesis) with or without the presence/absence of renal failure.23,24 Regarding performance status (PS) assessment,9,10 it is important to highlight that PS assessment should incorporate tumour-related symptoms but not baseline symptoms already present prior to cancer diagnosis and thus, related to pre-existing comorbidities. This can be difficult to differentiate

Keywords: HCC; survival; BCLC; ablation; surgery; liver transplantation TACE; TARE; systemic treatment; ALBI score; AFP.

Received 18 October 2021; received in revised form 15 November 2021; accepted 17 November 2021; available online 19 November 2021

1BCLC group, Liver Unit, ICMDDM, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; 2Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain; 3BCLC group, Radiology Department, CDI, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; 4BCLC group, Surgery Department, ICMDDM, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; 5BCLC group, Vascular Department, CDI, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; 6Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA; 7Department of Internal Medicine, Mainz University Medical Center, Mainz, Germany; 8Department of Oncology, University of Milan and HPB Surgery and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; 9Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA; 10Liver Unit, Clínica Universidad de Navarra, Pamplona, Spain; 11Department of Internal Medicine, University
when PS impairment is related to liver dysfunction, which may or may not be related to tumour burden.

Clinical research trials include BCLC staging in the definition of the target population, while at the same time they establish inclusion/exclusion criteria to define the patient’s profile. In clinical practice, the evaluation of a patient’s status incorporates BCLC staging and, simultaneously, the expert and personalised approach of the treating physician and multidisciplinary tumour board who will also consider tumour extension and burden, nutritional status, comorbidities and frailty, age, social status and human values and beliefs. Molecular profiling still cannot predict patient outcomes, risk of recurrence after successful surgery or ablation, or the best treatment option.18

As known, clinical practice guidelines and algorithms such as the BCLC model17 reveal the current state of knowledge and degree of scientific evidence available for each intervention but the ultimate decision must be taken by the responsible physician and tumour board, who need to assimilate all variables and recommend a given path of care for the patient as an individual. The multidisciplinary approach is key from the initial diagnosis and tumour staging through to defining the best initial and sequential treatment strategy. Expert radiologists, interventional radiologists, radiation oncologists, pathologists, nurses, clinicians, surgeons in the field of HCC and palliative care specialists and social workers need to work together for this purpose. Healthcare teams are responsible for performing and/or interpreting imaging techniques and pathology samples, to ultimately integrate all those data with the individual patient’s medical profile. In this regard, the personalised management of patients goes beyond factors related to HCC and liver function. Therefore, clinical decision-making and treatment recommendations should not merely be based on a simplified figure but on a complex process that requires personal insights and expertise.

Treatment

In the following paragraphs we describe the proposed treatment options for each BCLC stage. We also emphasise that while a given option should be considered first, expert evaluation of all the clinical and sociocultural information may result in two important concepts: treatment stage migration (TSM) and untreated progression. TSM is applied when a specific patient profile may induce a shift of the recommendation to the option that would be considered a priority for a more advanced stage. Untreatable progression was developed for patients under transarterial chemoembolisation (TACE) but applies to all BCLC stages and treatments. It represents failure of the selected treatment strategy. It emerges when patients present treatment failure or progression but still fit into their initial BCLC stage, thus warranting the consideration of a therapy corresponding to a more advanced stage. The 2022 BCLC treatment strategy (Fig. 1) incorporates a specific section to help guide an individualised approach to clinical decision-making, according to the available data on November 15, 2021.

It is worth stressing that while at first sight the BCLC model (Fig. 1) displays a given option that should be considered first, the specific profile of an individual patient may induce a shift in the recommendation to a treatment considered a priority for a more advanced stage (TSM concept). In some cases, treatment may shift from that initially recommended for early stage, to that recommended for advanced stage, or even to no treatment.

Very early stage (BCLC 0)

This is defined as a solitary HCC ≤2 cm without vascular invasion or extrahepatic spread in a patient with preserved liver function and no cancer-related symptoms.

BCLC-0 management varies according to the potential access to liver transplantation (LT) and specific profiles as depicted in the clinical decision-making section. The potential for LT should be considered because of the high recurrence risk, as already described in the last BCLC model. Therefore, if transplantation is an option and patients fulfil the criteria for surgery, resection should be the first choice. Pathology patterns indicative of increased recurrence risk (microscopic vascular invasion, satellites) may induce the consideration of LT because of such risk. However, local regulations for enlistment and priority policies may preclude effective transplant for BCLC-0 until recurrence is apparent. If LT is not feasible, the first treatment approach would be ablation, which is associated with similar survival outcomes to resection. Those patients with very small HCCs who present with severe liver dysfunction/decompensation may be considered for LT if they fulfil the enlistment criteria. Those not eligible for LT due to non-HCC factors, patients should be classified as BCLC stage D because of their dismal predicted survival. Indeed, patients may receive priority because of their end-stage liver status, while the presence of very early HCC is not considered as the reason for enlistment and/or for priority allocation.

Early stage (BCLC-A)

This is defined as solitary HCC irrespective of size or as a multifocal HCC up to 3 nodules (none of them >3 cm), without macrovascular invasion, extrahepatic spread or cancer-related symptoms (PS-0). Liver function must be preserved and not have reached LT criteria, at which point the patient would be classified as BCLC stage D because of their dismal prognosis outside of LT eligibility. As
Contraindications to LT

- Terminal stage (D)
  - Any tumor burden
  - End stage liver function, PS 3-4

- Very early stage (0)
  - Single ≤2 cm
  - Preserved liver function, PS 0

- Early stage (A)
  - Single, or ≤3 nodules each ≤3 cm
  - Preserved liver function, PS 0

- Intermediate stage (B)
  - Multinodular
  - Preserved liver function, PS 0

- Advanced stage (C)
  - Portal invasion and/or extrahepatic spread
  - Preserved liver function, PS 1-2

HCC

Based on tumor burden, liver function and physical status
Refined by AFP, ALBI score, Child-Pugh, MELD
To decide individualized treatment approach

Treatment stage migration primes lower priority options due to non-liver related clinical profile
(Age, comorbidities, patient values and availability)

Expected survival
- >5 years
- >2.5 years
- >2 years
- 3 months

Clinical decision-making

Potential candidate for liver transplantation
- Single
- ≤3 nodules, each ≤3 cm

Diffuse, infiltrative, extensive bilobar liver involvement

Portal pressure, bilirubin
- Normal
- Increased

Contraindications to LT
- Yes
- No

Potential candidate for liver transplantation
- Yes
- No

Treatment stage migration
Primes lower priority options due to non-liver related clinical profile
(Age, comorbidities, patient values and availability)

Potential candidate for liver transplantation
- Single
- ≤3 nodules, each ≤3 cm

Diffuse, infiltrative, extensive bilobar liver involvement

Portal pressure, bilirubin
- Normal
- Increased

Contraindications to LT
- Yes
- No

Potential candidate for liver transplantation
- Yes
- No

Potential candidate for liver transplantation
- Yes
- No

Potential candidate for liver transplantation
- Yes
- No

Potential candidate for liver transplantation
- Yes
- No

Potential candidate for liver transplantation
- Yes
- No

Potential candidate for liver transplantation
- Yes
- No

FIG. 1. BCLC staging and treatment strategy in 2022. The BCLC system establishes a prognosis in accordance with the 5 stages that are linked to first-line treatment recommendation. The expected outcome is expressed as median survival of each tumour stage according to the available scientific evidence. Individualised clinical decision-making, according to the available data on November 15, 2021, is defined by teams responsible for integrating all available data with the individual patient’s medical profile. Note that liver function should be evaluated beyond the conventional Child-Pugh staging. AFP, alpha-fetoprotein; ALBI, albumin-bilirubin; BCLC, Barcelona Clinic Liver Cancer; BSC, best supportive care; ECOG-PS, Eastern Cooperative Oncology Group-performance status; LT, liver transplantation; MELD, model of end-stage liver disease; TACE, transarterial chemoembolisation.
mentioned above, those patients with liver disease deserving LT consideration should be evaluated in the framework of end-stage liver disease. In such settings, a diagnosis of HCC could become an exclusion criterion for LT if exceeding the enlistment criteria.42–47 If LT is contraindicated due to non-HCC factors, there is no effective option to be offered. Thus, the patient should be classified as BCLC stage D.

The treatment approach for BCLC-A patients varies according to tumour number and degree of liver function impairment.

Solitary HCC
Treatment selection in these patients requires a multiparametric approach.38 Liver function assessment should be stratified according to the degree of portal hypertension as it has been established that the presence of CSPH (defined by a hepatic venous pressure gradient [HVPG] >10 mmHg) predicts a higher rate of postoperative complications and a lower long-term survival.39–41 It is important to note that the accuracy of HVPG measurement is controversial in patients with non-alcoholic fatty liver disease.52,53

In the absence of CSPH, patients are considered for resection, and the recommendation should consider tumour burden and location, as well as potential candidacy for LT if the pathology profile of a resected HCC indicates a high risk of recurrence35–37; microvascular invasion and satellites are well-known recurrence predictors and because of such increased risk, LT may be considered if they are present.35–37 If no decision is to be derived from pathological examination, the survival offered by ablation in patients with HCC ≤3 cm may be competitive with that offered by resection.38–40,54–56 Because of less invasiveness and cost, ablation could be given priority. However, resection may be preferred for larger nodules and those in high-risk locations for ablation, for instance, adjacent to the gallbladder (see clinical decision-making section).52

If patients present with CSPH, surgical resection should be considered of significant risk26,58 and LT offers improved medium- and long-term survival. However, patients may not be considered for LT because of any characteristic and ablation has limited efficacy for large HCC. Therefore, laparoscopic resection could be considered if HCC is in the appropriate location and there is a minor degree of CSPH.74,75,77–79 Unfortunately, no portal pressure cut-off value may be given for such a decision and no robust recommendation can be made.

Multifocal within Milan criteria (up to 3 HCC nodules, each ≤3 cm)
Multifocal disease still within the Milan criteria42 is better served by LT, as ablation and resection are hampered by a high risk of HCC recurrence.64–66 If LT is not feasible, it is a matter of debate if outcome after surgery or ablation is better than that offered by TACE.47–48 Prospective clinical research is mandatory to define when surgical resection or ablation should be given priority over TACE for patients with up to 3 nodules. This may provide very competitive survival figures in early-stage patients with preserved liver function and health status.

Intermediate stage (BCLC-B)
This is defined as multifocal HCC (exceeding BCLC-A criteria) with preserved liver function, no cancer-related symptoms (PS 0) and no vascular invasion or extrahepatic spread. As well known, the magnitude of tumour burden may be quite heterogeneous in this stage, and prognosis is also influenced by AFP concentration69 and the degree of liver function impairment even if still belonging to Child-Pugh class A.16 However, robust cut-offs are not available. This individualised patient profile may also determine whether LT, TACE or systemic therapy should be favoured.70,71 The 2022 BCLC version stratifies the BCLC-B stage into 3 groups of patients according to tumour burden and liver function.

The first subgroup within BCLC-B includes patients with well-defined HCC nodules. These patients could be candidates for LT if they meet the ‘Extended Liver Transplant criteria’ according to the criteria of the Institution.72 Expansion of the criteria for LT has been proposed for several years.42–47 A minor increase in tumour size or number may provide competitive survival figures, hampered by a slight increase in recurrence that impairs long-term survival.73 The same has been reported if patients are allowed to develop a limited asymptomatic progression beyond Milan criteria.34 Survival may be competitive with that of patients within Milan criteria, but always at a cost of higher recurrence and lower long-term survival. Accordingly, the decision to accept extended criteria is defined by the impact of such expansion on access to LT for other indications and the minimal outcome that should be achieved for each indication.75 Elevated AFP values predict a higher risk of HCC recurrence and thus, lower survival. Several groups have established a concentration limit beyond which LT is not considered.45,46,70 A 1,000 ng/dl cut-off value is currently applied as an exclusion criterion. While downstaging therapy may induce a reduction of AFP, there are no robust data to define the magnitude and/or duration of reduction required before considering LT.75

The second subgroup comprises patients without the option of LT but who have preserved portal flow and defined tumour burden, suggesting the feasibility of selective access to feeding tumour arteries. They are candidates for TACE. If patients neither meet the ‘Extended liver transplant criteria’ nor the TACE criteria to secure
optimal outcomes, systemic therapy should be considered.

The third subgroup within BCLC-B includes patients with diffuse, infiltrative, extensive HCC liver involvement. They do not benefit from TACE, and systemic therapy should be the recommended option, although there is no strict cut-off for when this is the case.

**Advanced stage (BCLC-C)**

This stage includes patients presenting with vascular invasion or extrahepatic spread who are still relatively fit, as reflected by a PS ≤2 at staging work-up, and who have preserved liver function. BCLC-C patients should be evaluated for systemic therapy. Different effective options for first-, second- and following lines are currently available if patients fulfill the characteristics defined in the registration trials that led to regulatory approval. The combination of atezolizumab with bev-acizumab (Atezo-Bev) is currently the first-choice first-line treatment, as it confers a superior survival benefit compared to sorafenib, while it has not been evaluated head-to-head vs. lenvatinib. To benefit from Atezo-Bev, patients must present preserved liver function (compensated Child-Pugh A if there is underlying cirrhosis) and absence of high-risk stigmata for bleeding on upper endoscopy, e.g. properly treated oesophageal varices and no history of variceal bleeding, in order to minimise bleeding risk. Additional requirements that may prevent treatment include vascular disorders and arterial hypertension, as well as severe autoimmune disorders and prior transplantation.

Data from the phase III HIMALAYA trial showed that a single priming dose of tremelimumab added to durvalumab provided a statistically significant survival benefit vs. sorafenib and durvalumab as monotherapy is not inferior to sorafenib in first-line. Hence, availability of all the study data will likely impact on clinical decision-making in this setting. On November 20, the report of the COSMIC 132 trial testing the combination of cabozantinib and atezolizumab showed a significant benefit in progression-free survival (hazard ratio 0.63), but while waiting for the final survival analysis, the interim data do not show a significant survival benefit compared to sorafenib.

The treatment landscape following disease progression or toxicity (leading to treatment interruption) has gained complexity. Prior to 2020, sorafenib was the only effective first-line option for which evidence-based sequential treatment could be proposed. Patients transitioning to the second-line setting benefit from regorafenib if they are tolerant to sorafenib, from cabozantinib irrespective of tolerance to sorafenib, or ramucirumab if AFP level is >400 ng/dl and irrespective of tolerance to sorafenib. Cabozantinib is also effective as a third-line treatment.

A Western trial comparing pembrolizumab vs. placebo in second-line did not meet its primary overall survival endpoint, but an Asian trial in a similar population reported a significant survival improvement.

**End-stage (BCLC-D)**

Patients with major cancer-related symptoms (PS >2) and/or impaired liver function without the option of LT due to HCC burden or non-HCC-related factors present poor short-term survival and belong to the BCLC stage D. Development of HCC in patients with advanced liver disease who would otherwise be considered for LT may mandate their enlistment if tumour burden does not exceed the established criteria. Accordingly, owing to chronic liver disease, treatment of HCC will not change expected survival and would be of no benefit. In such instances, symptomatic management and coordination of palliative care are mandatory.

According to the BCLC proposal, the expected median survival of patients with HCC should be more than 5 years, 2.5 years, 2 years and 3 months for BCLC 0/A, B, C and D, respectively.

**Clinical decision-making**

The 2022 BCLC strategy incorporates an expert clinical decision-making component (Fig. 1). It highlights the different concepts and parameters that physicians and multidisciplinary tumour boards should integrate into a personalised HCC treatment approach.

**BCLC-0 patients**

Decisions in BCLC-0 may be modulated by several factors that preclude a certain treatment and justify a different recommendation from that proposed in the patient characterisation block of Fig. 1.

Ablation through radiofrequency (RF) or microwave (MW) is the preferred technique, while percutaneous ethanol injection is still applied in selected patients when there are technical or safety concerns. If ablation (percutaneous or laparoscopic if needed) is not feasible for any reason (location, availability etc.), the patient may be considered for surgical resection with the feasibility and safety assessment detailed in the BCLC-A section. When this option is not feasible, TACE is the preferred option. Transarterial radioembolisation (TARE) is equally effective. Stereotactic body radiation bears antitumoral activity but further prospective studies are needed to define its role. However, while safety and efficacy data are well established for RF and MW, TARE could be considered in patients with single nodules ≤8 cm. This new BCLC recommendation is based on the results of the Legacy study, which included patients with single nodules less than 8 cm, Child-Pugh A and Eastern Cooperative Oncology Group-PS 0/1. It is important to emphasise that the...
median tumour size of the patients included in that study was 2.6 cm (range 0.9–8.1). If the patient is not a candidate for locoregional treatment, the option of systemic treatment should be considered, but always aligned with the inclusion and exclusion criteria for the available agents with proven survival benefit.

BCLC-A patients
Resection and RF ablation offer the same survival benefit for HCC ≤2 cm. Ablation beyond this size is less effective and the lower rate of complete responses and higher rate of local recurrences means that resection should be favoured in such cases. MW achieves more extensive tumour necrosis than RF and is potentially the best option for those patients with HCC ≤4 cm. Larger tumours may still benefit from resection as size alone should not be considered a limiting factor for surgical resection, as long as imaging has not identified vascular invasion and the remnant liver volume permits adequate postoperative liver function. Radiation lobectomy by TARE may increase remnant liver volume and could be considered in some patients.

Major hepatectomy carries excessive risk in patients with cirrhosis and specific tumour locations may also prevent resection, leading to the consideration of LT. In such instances, size may be a limiting factor for LT according to the expanded criteria in place. Finally, large tumours are frequently associated with cancer-related symptoms (e.g., pain) and this portends poor outcomes after resection.

Upon enlisting patients for LT and if the expected waiting time exceeds 6 months, it is recommended to consider treatment to prevent tumour progression that could rule out LT. Ablation, chemoembolisation and TARE are the most widely used options for this purpose.

Laparoscopic/robotic resection allows for adequate margins and is less invasive, with fewer postoperative complications and a potentially non-significant impact on liver function even in patients with CSPH. These encouraging results may indicate resection in patients who would initially be selected for ablation, but in whom the peripheral tumour location may contraindicate such an approach because of the risk of tract seeding (if punctured without a protective rim ofnon-tumoural liver) or neighbouring organ damage. While an acceptable increased CSPH value has not been defined, it is worth considering that postoperative mortality increases and 1-year survival decreases in parallel with portal hypertension even if the surgery does not involve the liver.

As proposed for BCLC stage 0, if a patient is not a candidate for any of the mentioned approaches the concept of TSM should be applied and treatment with TACE should be considered, as well as TARE in patients who meet the Legacy inclusion criteria. This is a retrospective cohort study in which median tumour size was <3 cm and thus, validation by other groups is eagerly awaited. If TARE is also not feasible, systemic therapy should be considered.

The 2022 version of the BCLC staging system does not recommend resection for multinodular HCC within Milan criteria. Cohort studies of resection report encouraging survival results but prospective data are needed to establish the effectiveness of such an approach compared to locoregional approaches. Thus, TACE is the preferred option if the first treatment option is not feasible. However, large tumours exceeding 8–10 cm are reported to be associated with worse outcomes after TACE; this potentially being related to the potential impairment of portal venous flow due to invasion or compression, rather than to the impact of major tumour necrosis. Furthermore, patients with large tumours are rarely free from symptoms. If these are present the patients should be classified as BCLC-C. Indeed, survival of symptomatic patients (PS 1) after TACE is significantly lower than that of asymptomatic patients.

BCLC-B patients
For patients to be candidates for TACE, liver function has to be well preserved. Increased bilirubin beyond 2 mg or slight fluid retention requiring diuretic treatment are associated with an increased risk of adverse events and suboptimal survival after TACE. It is not possible to define strict evidence-based criteria to recommend TSM (favouring systemic treatment), so expert assessment is key to secure optimal care. Ongoing trials comparing TACE vs. systemic therapy for BCLC-B patients have detailed inclusion and exclusion criteria and may produce very useful information that will guide clinical practice.

TACE might be performed using chemotherapy emulsified in lipiodol followed by gelfoam or any other material injection (conventional TACE) or using drug-eluting microspheres (DEB-TACE). The first is associated with a peak of chemotherapy in the systemic circulation that may increase toxicity and lead to higher post-procedural pain, while DEB-TACE has a favourable pharmacokinetic profile. Response rates and survival are not different between the techniques. Thus, each team has to define its preference. Available clinical trials comparing bland embolisation to TACE are not informative as the population included does not match the profile of patients for whom TACE would be recommended. Meta-analytic assessment is hampered by excessive heterogeneity between trials.

Systemic treatment is the recommended option for those BCLC-B patients who are not candidates.

Key point
Evaluation and management of patients with liver cancer has to integrate baseline patient profiles and evolutionary events.

Key point
The treatment of BCLC-B patients has to be tailored according to tumour burden and effective downstaging may allow for liver transplantation.
for TACE for any reason.78–81,84,85,87 If not candidates for systemic treatment, entry into clinical trials should be considered.

Although the Milan criteria are still largely applied to select patients with HCC for LT, an increasing number of studies have shown that acceptable post-LT survival may be obtained in a selected group of patients at BCLC stage B beyond Milan criteria. Several selection criteria that sought to expand the Milan criteria have been proposed and revised elsewhere.72 Consensus on expanded criteria for LT in HCC has not been reached. However, composite criteria that consider surrogates of tumour biology (AFP being the most frequently explored) and response to neoadjuvant treatments, are likely to replace conventional morphological criteria for defining transplant feasibility. Several AFP cut-offs have been used to exclude LT.45,46,76,112 with values beyond 1,000 ng/ml widely accepted as a contraindication for LT.45,46,112 Patients with an AFP >1,000 ng/ml who experienced biochemical response (at least a decrease to less than 500 ng/ml) to locoregional therapies have post-LT outcomes comparable to those reported for patients within Milan criteria.77 Downstaging has emerged as a reliable tool for selecting patients for LT. The goal of downstaging is to reduce tumour burden in order for residual viable tumours to fall within acceptable LT criteria, with Milan criteria being the commonest endpoint of downstaging.113,114 The upper limit of where a downstaging approach is considered varies across LT regions. This also affects the specific imaging criteria used to define baseline and post-treatment staging and evaluation of response. Further studies are needed to validate such an approach and to establish how best to apply a downstaging protocol. It is important to note that the need to carefully establish the patient profile that defines a good transplant candidate is due to the shortage of donors. It implies a demand to use the available donors to provide the best outcome for the community and not solely the individual. Live donation may circumvent this challenge, although whether to use the same criteria as for cadaveric donors or to accept a moderate expansion or a downstaging success is still controversial.72 Again, survival may be competitive but the balance between donor risk and patient benefit is not homogeneously perceived in different cultural settings.

**BCLC-C patients**

Atezo-Bev provides survival benefit over sorafenib with some patients exhibiting prolonged complete responses. Real-life data will reveal the proportion of patients excluded from the IMbrave150 clinical trial due to comorbidities or associated bleeding risk due to portal hypertension. The combination of tremelimumab and durvalumab has been reported to be superior to sorafenib, adding another first-line treatment option.92 A significant proportion of patients with advanced HCC may not be appropriate candidates for either Atezo-Bev or tremelimumab and durvalumab as monotherapy; TKIs (sorafenib or lenvatinib) could still be considered in cases where the previous options are contraindicated.29 In this regard, selection of the appropriate option relies on the careful analysis of the clinical, radiological and biochemical profile of the patient, so that they fit into the target population enrolled in the trials where safety and efficacy was demonstrated. Prospective studies of data in real life may broaden the treatment indication, but in its absence, the recommendation is to retain the clinical and biochemical profile defined in registration trials.29 Furthermore, real-world data may be informative but will never replace the strength of randomised trials as evidence of a survival benefit.115 Safety in specific populations may be established but survival benefit in the absence of randomised trials will remain speculative.

Even though Atezo-Bev is the preferred first-line option,78 the results of the study on tremelimumab-durvalumab will impact on the
choice of first-line treatment. If these options are not feasible for any reason, consideration has to be given to the fact that both lenvatinib and single agent durvalumab are non-inferior to sorafenib, but recalling that there is a major need to assess if the available second-line alternatives retain their effectiveness in patients initially receiving either of these options. Further, it needs to be evaluated if sorafenib, lenvatinib or durvalumab should be considered as “de facto” second-line options or if their effectiveness could be modified after Atezo-Bev or tremelimumab-durvalumab. No robust information is available, thus preventing evidence-based recommendations. Several trials that may clarify some of the current unknowns are ongoing and, they may or may not increase the first-line alternatives and/or change the sequential treatment schedule currently in place. In that sense, as the efficacy of new strategies increases in terms of response and reduction of tumour burden, the registered downstaging may allow some patients to benefit from potentially curative options that were initially discarded because of excessive tumour load.

TARE has also been suggested to be as effective as sorafenib in patients with liver-only involvement. However, prospective phase III trials comparing it with sorafenib or combining it with sorafenib vs. sorafenib alone have failed to demonstrate its superiority and were not designed to prove non-inferiority. Therefore, no evidence-based recommendation can be made until positive trials are available.

**Evolutionary events and clinical decision-making process**

**BCLC staging upon progression after initial diagnosis**

It is conventional in oncology to consider tumour progression as a dismal event that is taken as a reflection of treatment failure and the need to transition to another line of therapy. However, it is well established that patients treated with surgical resection, ablation or TACE may present progression at new intrahepatic sites after successful treatment of the first tumour nodule. In some instances, treatment may be repeated, and the tumour again brought under control with potential complete response. Indeed, progression may have different patterns with sharply different meaning in terms of prognosis and potential treatment. This concept was raised years ago for patients treated by TACE. Treatment may be successful, but new tumour sites may appear during follow-up. These may be amenable to new TACE if just intrahepatic and if the patient profile has not changed in terms of liver function and physical status. Contrarily, if progression is due to portal vein invasion or extrahepatic spread or cancer-related symptoms, or if liver function is significantly impaired, new TACE sessions are not recommended. In such instances, the patient is registered as presenting untreatable progression and systemic therapy may be considered. This specific progression scenario implies a different prognosis and a different treatment recommendation and hence, offers more clinical insight than the commonly used term “progression”. The heterogeneity of both progression patterns and individual patient profiles at progression mandate multidisciplinary team discussions to identify the best treatment option for a given patient.

The same need to stratify the pattern of progression has emerged in patients undergoing systemic therapy. Prospective studies have demonstrated that prognosis after progression due to increased growth of known tumour sites or new intrahepatic sites is significantly better than progression due to new extrahepatic involvement or vascular invasion. This primed the proposal of a BCLC prognostic model upon progression that is depicted in Fig. 2. As shown, patients may start systemic therapy either in BCLC stage B or C. Those initially at stage B may progress but remain within the definitions of stage B, being classified as BCLCp-B. Those initially at BCLC stage C may show growth of existing lesions or new intrahepatic sites and be classified as BCLCp-C1 or develop new vascular invasion or extrahepatic spread and then be registered as BCLCp-C2.

![Key point](https://example.com/key_point)

**Tumour progression and/or treatment-related adverse events may lead to treatment recommendations that would usually be for a more advanced stage even if BCLC stage has not changed (treatment stage migration).**
to personalise decisions at the tumour board level, incorporating the concepts of TSM and untreatable progression. However, no algorithm should be expected to provide exhaustive guidance for each patient. A multiparametric evaluation should be in place for every patient and this should be integrated into multidisciplinary tumour boards where all partners involved in care are actively involved. For an effective output from such boards, it is key to have a clearly established initial approach from where to reach individual decisions. The updated BCLC model and its regular update serves this purpose.

**Abbreviations**

AFP, alpha-fetoprotein; Atez-Bev, atezolizumab with bevacizumab; BCLC, Barcelona Clinic Liver Cancer; CSPH, clinically significant portal hypertension; HCC, hepatocellular carcinoma; HVPG, hepatic venous pressure gradient; LT, liver transplantation; MELD, model for end-stage liver disease; MW, microwave; PS, performance status; RF, radio-frequency; TACE, transarterial chemoembolisation; TARE, transarterial radioembolisation; TSM, treatment stage migration.

**Financial support**

MR: Dr. Reig’s research is partially supported by Instituto de Salud Carlos III (PI15/00145 and PI18/0358) and from the Spanish Health Ministry (National Strategic Plan against Hepatitis C). AF: Dr. Forner’s research is partially supported by Instituto de Salud Carlos III (PI13/01229 and PI18/00542). JR: Dr. Rimola’s research is partially supported by grant from European Association for the Study of the Liver (EASL). BS: Dr. Sangro’s research is partially supported by ISCIII/EU TRANSCAN-2 (AC16/00065), and Instituto de Salud Carlos III (PI19/00742). AS: Dr. Singal’s research is supported by National Institute of Health R01 R01 MD012565. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. JB: Dr. Bruix’s research is partially supported by Instituto de Salud Carlos III (PI18/00768), the Spanish Health Ministry (National Strategic Plan against Hepatitis C) and AECC (PI044031). CIBERehd: is funded by the Instituto de Salud Carlos III. Dr. Rimola, Dr. Reig and Dr. Bruix are partially funded from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 952103.

**Conflict of interest**

MR: reports consultancy from Bayer, BMS, Roche, Ipsen, Astra Zeneca, Boston Science and Lilly; lecture fees from Bayer, BMS, Gilead, Lilly, Roche and UniversalDX and travel support from Bayer, BMS, Lilly and Astra Zeneca. Received research funding (to institution) from Bayer and Ipsen. AF: reports lecture fees from Bayer, Boston Science, Gilead, and MSD; consultancy fees from Bayer, Astra Zeneca, Roche, SIRTEx, AB Exact Science and Guerbert. JR: reports lectures and travel grants from Bayer and Roche. JFF: reports lecture fees from Bayer. MB: reports lectures and/or travel support from Boston Science, Terumo, Guerbert and Bayer. AGC: reports lecture fees from Boston Science, Terumo. KRK: reports consultancy fees (to self) from Exact Sciences, Genentech/Roche, Gilead. Received travel support from Ipsen. Received research funding (to institution) from Agios, Astra Zeneca, Bayer, BMS, Eli Lilly, EMD Serono, Exelixis, Genentech/Roche, Merck, Novartis, Partner Therapeutics, QED, Relay Therapeutics, Surface Oncology, Taiho. PRG: consultancy fees and/or travel support from Bayer, Boston Scientific, AstraZeneca, Adaptimmune, BMS, MSD, Sirtex, Lilly, Roche, Guerbet, Ipsen, Eias, VM: Nothing to disclose. RS: reports consultancy fees from Boston Scientific, Cook, Bard, Genentech, Astrazeneca, Eias, Sirtex, Siemens, research support from Boston Scientific. BS: reports consultancy fees from Adaptimmune, Astra Zeneca, Bayer, BMS, Boston Scientific, BTG, Eias, Eli Lilly, H3 Biomedicine, Ipsen, Novartis, Merck, Roche, Sirtex Medical, Terumo; speaker fees from Astra Zeneca, Bayer, BMS, BTG, Eli Lilly, Ipsen, Novartis, Merck, Roche, Sirtex Medical, Terumo; research grants (to Institution) from BMS and Sirtex Medical. AS: has served on advisory boards or consulted for Genentech, Bayer, Eias, AstraZeneca, BMS, and Exelixis. AV: Speaker, consultancy and advisory role: Amgen, Roche, Bayer, Sanofi, BMS, Lilly, Novartis, Eias, AstraZeneca, Merck, Incyte, Ipsen, PierreFabre, MSD, Sirtex, BTG, Servier, Terumo, GSK. JFu: Nothing to disclose. CA: reports lectures fee from Bayer. JB: has consulted for Arqule, Bayer-Shering Pharma, Novartis, BMS, BTG–Biocompatibles, Eias, Kowa, Terumo, Gilead, Bio-Alliance, Roche, AbbVie, MSD, Sirtex, Ipsen, Astra-Medimmune, Incyte, Quirem, Adapimmune, Lilly, Basilea, Nerviano, Sanof and UniversalDX; and received research/educational grants from Bayer, and lecture fees from Bayer-Shering Pharma, BTG-Biocompatibles, Eias, Terumo, Sirtex, Ipsen. Please refer to the accompanying ICMJE disclosure forms for further details.

**Authors’ contributions**

Initial and final writing of the manuscript: MR and JB. Preparation of the figure: MR, AF, VM and JB. Critical reading and suggestions: All but MR and JB. Final approval: All authors.
References

**Author names in bold designate shared co-first authorship**


Acknowledgement

Some of the authors of this article are members of the European Reference Network on Hepatological Diseases (ERN RARE-LIVER).

Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jhep.2021.11.018.


